Boston Scientific anticipates Q4 2026 organic revenue down 3% to down 1% and adjusted EPS $0.77-$0.79 amid cyber and EP/WATCHMAN pressure (NYSE:BSX)

Boston Scientific expects Q4 2026 organic revenue to decline by 1% to 3% and adjusted EPS to be $0.77-$0.79, citing pressures from cyber and EP/WATCHMAN issues. The company's guidance reflects challenges in specific business segments.

Original reporting
Published Oct 28, 2026, 5:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Boston Scientific anticipates Q4 2026 organic revenue down 3% to down 1% and adjusted EPS $0.77-$0.79 amid cyber and EP/WATCHMAN pressure (NYSE:BSX) — source image
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

The guidance downgrade may trigger short‑term price weakness, but long‑term fundamentals remain solid.

02

Market read

Guidance update is the primary catalyst for BSX's near‑term price action.

03

What to watch

Potential cost‑saving initiatives or new product launches not reflected in the guidance.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Boston Scientific is a leading medical device maker; guidance reflects market headwinds from cyber‑security concerns and competition in its EP/WATCHMAN portfolio.

Company-level read

Ticker impact

$BSXBearishMedium confidence
Context

Boston Scientific provided Q4 2026 guidance forecasting organic revenue down 1‑3% and adjusted EPS $0.77‑$0.79.

Expected impact

potential downside as investors price in weaker revenue and EPS

Evidence & confidence

Revenue contraction and lower EPS guidance typically trigger sell pressure in the near term.

Market effects

May weigh on the broader medical device sector as peers could face similar margin pressure.

Limited to U.S. healthcare equities; no broader regional effect.

Low global relevance beyond sector.

Counterpoint

If the revenue dip is temporary and pipeline growth accelerates, the stock could rebound.

Key entities

  • Boston Scientific Corporation

    Medical device manufacturer providing the guidance.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.